Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT) [Phase 3]

View source ↗

Summary

ClinicalTrials.gov update for a Phase 3 study evaluating mitapivat in non-transfusion-dependent alpha- or beta-thalassemia; results were posted on 2025-01-24 an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-transfusion-dependent Alpha-thalassemia
• Non-transfusion-dependent Beta-thalassemia

Drugs mentioned

• Mitapivat (mitapivat)

Snippet

Sponsor: Agios Pharmaceuticals, Inc. | Conditions: Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-01-24